

# AssayMax™ Human IFN-gamma ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

# **Assay Summary**

**Step 1**. Add 50  $\mu$ l of Standard or Sample per well. Incubate 2 hours.

**Step 2.** Wash, then add 50  $\mu$ l of Biotinylated Antibody per well. Incubate 2 hours.

**Step 3**. Wash, then add 50  $\mu$ l of SP Conjugate per well. Incubate 30 minutes.

**Step 4.** Wash, then add 50  $\mu$ l of Chromogen Substrate per well. Incubate 25 minutes.

**Step 5.** Add 50  $\mu$ l of Stop Solution per well. Read at 450 nm immediately.

# **Symbol Key**



Consult instructions for use.

# **Assay Template**

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

# AssayMax™ Human Interferon-gamma (IFN-gamma) ELISA Kit

Catalog No. EI1023-1
Sample insert for reference use only

#### Introduction

Interferon-gamma (IFN-gamma) is a highly pleiotropic protein secreted mainly by activated T-lymphocytes and natural killer cells. It is involved in a wide range of physiological processes, including antiviral, immunoregulatory and anti-tumour properties, cell proliferation and apoptosis, as well as the stimulation and repression of a variety of genes (1-3). IFN-gamma is a homodimer consisting of two 143-amino-acid polypeptides, 20 kDa and 25 kDa, respectively (4). By binding to the receptors IFNGR1 & IFNGR2, IFN-gamma activates the tyrosine kinase JAK-STAT pathway (5). While protecting against tumor development and cancer immunoediting, IFN-gamma function is significant in tumor surveillance (6). Aside from functions in host defense, IFN-gamma may contribute to autoimmune pathology. In humans, IFN-gamma is implicated in pathology of diseases, such as systemic lupus erythematosus (7), multiple sclerosis (8), and insulin-dependent diabetes mellitus (9). Therapeutically, IFN-gamma administration enhances bone resorption and leukocyte function in patients with osteopetrosis (10).

### Principle of the Assay

The AssayMax™ Human Interferon-gamma ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of IFN-gamma in human plasma, serum, and cell culture samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human IFN-gamma in approximately 5 hours. A polyclonal antibody specific for human IFN-gamma has been pre-coated onto a 96-well microplate with removable strips. IFN-gamma in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human IFN-gamma, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

#### **Caution and Warning**

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial, the biotinylated antibody vial, and the standard diluent vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

#### Reagents

- Human IFN-gamma Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human IFNgamma.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human IFN-gamma Standard: Human IFN-gamma in a buffered protein base (75 pg, lyophilized).
- **Biotinylated Human IFN-gamma Antibody (30x):** A 30-fold concentrated biotinylated polyclonal antibody against human IFN-gamma (180 μl).
- **EIA Diluent Concentrate (10x):** A 10-fold concentrated buffered protein base (20 ml).
- Standard Diluent (1x): A buffered protein base with stabilizer (2 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

### **Storage Condition**

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Standard Diluent (1x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.

 Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

#### **Other Supplies Required**

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

#### Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 4-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 4-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. If necessary, dilute samples into EIA Diluent; user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)			
	100x		10000x	
A)	4 μl sample: 396 μl buffer (100x) = 100-fold dilution  Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.	
	1000x		100000x	
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution	
	Assuming the needed volume is less than or equal to 240 $\mu$ l.		Assuming the needed volume is less than or equal to 240 μl.	

#### **Reagent Preparation**

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** Dilute the EIA Diluent Concentrate 10-fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human IFN-gamma Standard: Reconstitute the Human IFN-gamma Standard (75 pg) with 0.6 ml of Standard Diluent to generate a 125 pg/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (125 pg/ml) 2-fold with equal volume of EIA Diluent to produce 62.5, 31.25, 15.625, 7.813, 3.906, 1.953, and 0.977 pg/ml solutions. EIA Diluent serves as the zero standard (0 pg/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 7 days.

Standard Point	Dilution	[IFN-gamma] (pg/ml)
P1	1 part Standard (125 pg/ml) + 1 part EIA Diluent	62.5
P2	1 part P1 + 1 part EIA Diluent	31.25
P3	1 part P2 + 1 part EIA Diluent	15.625
P4	1 part P3 + 1 part EIA Diluent	7.813
P5	1 part P4 + 1 part EIA Diluent	3.906
P6	1 part P5 + 1 part EIA Diluent	1.953
P7	1 part P6 + 1 part EIA Diluent	0.977
P8	EIA Diluent	0.0

- Biotinylated Human IFN-gamma Antibody (30x): Spin down the antibody briefly and dilute the desired amount of the antibody 30-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
  the concentrate, make sure to rinse the bottle thoroughly to extract any
  precipitates left in the bottle. Mix the 1x solution gently until the crystals
  have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with EIA Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

# **Assay Procedure**

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human IFN-gamma Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate
  washer. Invert the plate and decant the contents; hit 4-5 times on
  absorbent material to completely remove the liquid. If washing
  manually, wash five times with 200 µl of Wash Buffer per well. Invert the
  plate each time and decant the contents; hit 4-5 times on absorbent
  material to completely remove the liquid. If using a microplate washer,

- wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human IFN-gamma Antibody to each well.
   Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 25 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
   Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

#### **Data Analysis**

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

# **Typical Data**


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	pg/ml	OD	Average OD
P1	62.5	1.750	1.752
7-2	02.3	1.754	1.752
P2	31.25	1.473	1.458
r Z	31.23	1.443	1.436
P3	15.625	1.097	1.070
ro	15.025	1.043	1.070
P4	7.813	0.739	0.720
P4		0.701	0.720
P5	3.906	0.447	0.444
P3		0.441	0.444
P6	1.953	0.264	0.271
PO	1.955	0.278	0.271
P7	0.977	0.167	0.165
۴/	0.977	0.163	0.105
P8	0.0	0.036	0.035
rδ	0.0	0.034	0.035

#### **Standard Curve**

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human IFN-gamma Standard Curve



#### **Performance Characteristics**

- This assay recognizes both natural and recombinant human IFN-gamma.
- The minimum detectable dose of human IFN-gamma as calculated by 2SD from the mean of a zero standard was established to be 0.21 pg/ml.

- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Pred	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	4.0%	3.7%	4.8%	9.9%	9.1%	10.4%
Average CV (%)	4.2%				9.8%	

### Recovery

Standard Added Value	2 – 31.25 pg/ml	
Recovery %	91 – 112%	
Average Recovery %	98%	

# Linearity

• Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)			
Sample Dilution Plasma Serum		Serum	
2x	116%	100%	
4x	109%	110%	
8x	85%	90%	

# **Cross-Reactivity**

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Monkey	None
Mouse	None
Rat	None
Swine	80%
Rabbit	None

• 10% FBS in culture media will not affect the assay.

# **Troubleshooting**

Issue	Causes	Course of Action
	Use of improper	Check the expiration date listed before use.
	components	<ul> <li>Do not interchange components from different lots.</li> </ul>
		<ul> <li>Check that the correct wash buffer is being used.</li> </ul>
		<ul> <li>Check that all wells are empty after aspiration.</li> </ul>
	Improper wash step	<ul> <li>Check that the microplate washer is dispensing properly.</li> </ul>
		<ul> <li>If washing by pipette, check for proper pipetting</li> </ul>
_		technique.
Low Precision	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
re	Inconsistent volumes	<ul> <li>Pipette properly in a controlled and careful manner.</li> </ul>
>	loaded into wells	Check pipette calibration.
ò	loaded lifto Wells	<ul> <li>Check pipette for proper performance.</li> </ul>
	Insufficient mixing of	<ul> <li>Thoroughly agitate the lyophilized components after</li> </ul>
	reagent dilutions	reconstitution.
	reagent anations	Thoroughly mix dilutions.
		<ul> <li>Check the microplate pouch for proper sealing.</li> </ul>
	Improperly sealed	<ul> <li>Check that the microplate pouch has no punctures.</li> </ul>
	microplate	Check that three desiccants are inside the microplate
		pouch prior to sealing.
_	Microplate was left	Each step of the procedure should be performed
na	unattended between	uninterrupted.
gig	steps	
h S	Omission of step	Consult the provided procedure for complete list of steps.
Unexpectedly Low or High Signal Intensity	Steps performed in incorrect order	Consult the provided procedure for the correct order.
ה ה	Insufficient amount of	Check pipette calibration.
w e	reagents added to	Check pipette for proper performance.
ly Low or Intensity	wells	
2 ≧	Wash step was skipped	<ul> <li>Consult the provided procedure for all wash steps.</li> </ul>
je c	Improper wash buffer	<ul> <li>Check that the correct wash buffer is being used.</li> </ul>
ect	Improper reagent	<ul> <li>Consult reagent preparation section for the correct</li> </ul>
х	preparation	dilutions of all reagents.
ne	Insufficient or	<ul> <li>Consult the provided procedure for correct incubation</li> </ul>
<b>O</b>	prolonged incubation	time.
	periods	
		Sandwich ELISA: If samples generate OD values higher
#		than the highest standard point (P1), dilute samples
ē	Non-optimal sample	further and repeat the assay.
<u> </u>	dilution	<ul> <li>Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples</li> </ul>
ರ	unution	further and repeat the assay.
Ē		User should determine the optimal dilution factor for
qa		samples.
Deficient Standard Curve Fit	Contamination of	A new tip must be used for each addition of different
S	reagents	samples or reagents during the assay procedure.
ant	Contents of wells	Verify that the sealing film is firmly in place before placing
ĊĖ	evaporate	the assay in the incubator or at room temperature.
efi		Pipette properly in a controlled and careful manner.
	Improper pipetting	Check pipette calibration.
		Check pipette for proper performance.

	Insufficient mixing of reagent dilutions	<ul> <li>Thoroughly agitate the lyophilized components after</li> </ul>
		reconstitution.
		Thoroughly mix dilutions

#### References

- (1) Boehm U et al. (1997) Annu Rev Immunol. 15:749-795.
- (2) Schoenborn JR, Wilson CB. (2007) Adv Immunol. 96:41-101.
- (3) Schroder K et al. (2004) J Leukoc Biol. 75:163-189.
- (4) Rinderknecht E et al. (1984) J Biol Chem. 259:6790-6797.
- (5) Kaplan DH et al. (1996) J Biol Chem. 271:9-12.
- (6) Ikeda H et al. (2002) Cytokine Growth Factor Rev. 13:95-109.
- (7) Baechler EC et al. (2003) Proc Natl Acad Sci USA. 100:2610-2615.
- (8) Panitch HS et al. (1987) Lancet. 1:893-895.
- (9) Sarvetnick N et al. (1988) Cell. 52:773-782.
- (10) Key LL et al. (1992) J Pediatr. 121:119-124.

Version 2.2R1